

10201408158S

Text of the abstract

Use of a composition including at least one HMG-CoA reductase inhibitor and at least one farnesyl pyrophosphate synthase inhibitor for the treatment of skin ageing, premature skin ageing, premature myolipocutaneous ageing, progeria, lipodystrophy and/or restrictive dermopathy.